In this segment, experts review 6-year follow-up data from the SEQUOIA and ALPINE studies in CLL and SLL, with a focus on efficacy, safety, and treatment selection in the modern era. Ian Flinn, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results